Common use of Restricted Enzymes Clause in Contracts

Restricted Enzymes. 3.6.1 During the Term, in its ordinary course of business, Codexis will conduct research and development activities for itself and Third Parties under the Licensed IP using the Platform Technology and, in connection with such research and development activities, will generate Potentially Restricted Enzymes that, in certain cases, on a Potential Restricted Enzyme-by-Potentially restricted Enzyme basis, (a) will be owned in whole or in part by such Third Parties or exclusively licensed in whole or in part by Codexis to such Third Parties, (b) will not be Controlled by Codexis, or (c) Codexis otherwise has a reasonable basis to designate as a Potentially Restricted Enzyme. For purposes of this Section 3.6.1, the term “Potentially Restricted Enzyme” means any enzyme, or any vector that encodes for enzyme, derived from the use of the Platform Technology by Codexis after the Effective Date that, in either case, may not be Controlled by Codexis or is an enzyme that Codexis has a reasonable basis to designate as a Potentially Restricted Enzyme. In the event that any Potentially Restricted Enzyme generated by Codexis is not Controlled by Codexis or is an enzyme that Codexis has a reasonable basis to designate as a Potentially Restricted Enzyme, Codexis, subject to confidentiality obligations owed by Codexis to any Third Party, will inform the Patent Committee of such Potentially Restricted Enzyme at its next regularly scheduled meeting and amend the list of Restricted Enzymes set forth in Exhibit 1.97 to include the Potentially Restricted Enzyme. The Patent Committee will review information provided by Codexis with respect to any such Potentially Restricted Enzyme and, in accordance with Section 5.5.3, determine whether the list of Restricted Enzymes set forth on Exhibit 1.97 shall be revised to include such Potentially Restricted Enzyme and, if applicable, any particular field(s) and/or use(s) restrictions with respect to such Potentially Restricted Enzyme. The Patent Committee will create and maintain a list of all Potentially Restricted Enzymes.

Restricted Enzymes. 3.6.1 During the Term, in its ordinary course of business, Codexis will conduct research and development activities for itself and Third Parties under the Licensed IP using the Platform Technology and, in connection with such research and development activities, will generate Potentially Restricted Enzymes that, in certain cases, on a Potential Potentially Restricted Enzyme-by-by- Potentially restricted Restricted Enzyme basis, (abasis,(a) will be owned in whole or in part by such Third Parties or exclusively licensed in whole or in part by Codexis to such Third Parties, Parties and (b) will not be Controlled by Codexis, or (c) Codexis otherwise has a reasonable basis to designate as a Potentially Restricted Enzyme. For purposes of this Section 3.6.13.7.1, the term “Potentially Restricted Enzyme” means any enzymepeptide or protein, including derivatives, with enzymatic or biocatalytic activity, or any vector that encodes for enzymeany such peptide or protein, derived from the use of the Platform Technology by Codexis after the Effective Date that, in either case, may not be Controlled by Codexis or is an enzyme that Codexis has a reasonable basis to designate as a Potentially Restricted EnzymeCodexis. In the event that any Potentially Restricted Enzyme generated by Codexis is not Controlled owned by a Third Party or exclusively licensed by Codexis or is an enzyme that Codexis has to a reasonable basis to designate as a Potentially Restricted EnzymeThird Party, Codexis, subject to confidentiality obligations owed by Codexis to any such Third Party, will inform the Patent Committee of such Potentially Restricted Enzyme at its next regularly scheduled meeting and amend the list of Restricted Enzymes set forth in Exhibit 1.97 and, if applicable, any particular field(s) and/or use(s) restrictions with respect to include the such Potentially Restricted Enzyme. The Patent Committee will review information provided by Codexis with respect to any such Potentially Restricted Enzyme and, if applicable, any particular field(s) and/or use(s) restrictions with respect to such Potentially Restricted Enzymes and, in accordance with Section 5.5.35.2.3, determine whether the list of Restricted Enzymes set forth on Exhibit 1.97 1.112 shall be revised to include such Potentially Restricted Enzyme and, if applicable, any particular field(s) and/or use(s) restrictions with respect to such Potentially Restricted Enzyme. The Patent Committee Codexis will create and maintain a provide GSK with the initial list of all Potentially Restricted EnzymesEnzymes on Exhibit 1.112 within [***] days after the Effective Date.

Restricted Enzymes. 3.6.1 3.7.1 During the Term, in its ordinary course of business, Codexis will conduct research and development activities for itself and Third Parties under the Licensed IP using the Platform Technology and, in connection with such research and development activities, will generate Potentially Restricted Enzymes that, in certain cases, on a Potential Potentially Restricted Enzyme-by-by- Potentially restricted Restricted Enzyme basis, (abasis,(a) will be owned in whole or in part by such Third Parties or exclusively licensed in whole or in part by Codexis to such Third Parties, Parties and (b) will not be Controlled by Codexis, or (c) Codexis otherwise has a reasonable basis to designate as a Potentially Restricted Enzyme. For purposes of this Section 3.6.13.7.1, the term “Potentially Restricted Enzyme” means any enzymepeptide or protein, including derivatives, with enzymatic or biocatalytic activity, or any vector that encodes for enzymeany such peptide or protein, derived from the use of the Platform Technology by Codexis after the Effective Date that, in either case, may not be Controlled by Codexis or is an enzyme that Codexis has a reasonable basis to designate as a Potentially Restricted EnzymeCodexis. In the event that any Potentially Restricted Enzyme generated by Codexis is not Controlled owned by a Third Party or exclusively licensed by Codexis or is an enzyme that Codexis has to a reasonable basis to designate as a Potentially Restricted EnzymeThird Party, Codexis, subject to confidentiality obligations owed by Codexis to any such Third Party, will inform the Patent Committee of such Potentially Restricted Enzyme at its next regularly scheduled meeting and amend the list of Restricted Enzymes set forth in Exhibit 1.97 and, if applicable, any particular field(s) and/or use(s) restrictions with respect to include the such Potentially Restricted Enzyme. The Patent Committee will review information provided by Codexis with respect to any such Potentially Restricted Enzyme and, if applicable, any particular field(s) and/or use(s) restrictions with respect to such Potentially Restricted Enzymes and, in accordance with Section 5.5.35.2.3, determine whether the list of Restricted Enzymes set forth on Exhibit 1.97 1.112 shall be revised to include such Potentially Restricted Enzyme and, if applicable, any particular field(s) and/or use(s) restrictions with respect to such Potentially Restricted Enzyme. The Patent Committee Codexis will create and maintain a provide GSK with the initial list of all Potentially Restricted EnzymesEnzymes on Exhibit 1.112 within [***] days after the Effective Date.